


Lewis Acid Triggered Regioselective Magnesiumation and Zincation of Uracils, Uridines, and Cytidines

Lydia Klier, Eider Aranzamendi, Dorothee Ziegler, Johannes Nickel, Konstantin Karaghiosoff, Thomas Carell, and Paul Knochel*

Department Chemie, Ludwig-Maximilians-Universität, Butenandtstrasse 5-13, 81377 München, Germany

S Supporting Information

ABSTRACT: The Lewis acid MgCl_2 allows control of the metalation regioselectivity of uracils and uridines. In the absence of the Lewis acid, metalation of uracil and uridine derivatives with $\text{TMPMgCl}\cdot\text{LiCl}$ occurs at the position C(5). In the presence of MgCl_2 , zincation using $\text{TMP}_2\text{Zn}\cdot 2\text{LiCl}\cdot 2\text{MgCl}_2$ occurs at the position C(6). This metalation method provides easy access to functionalized uracils and uridines. Using $\text{TMP}_2\text{Zn}\cdot 2\text{LiCl}\cdot 2\text{MgCl}_2$ also allows to functionalize cytidine derivatives at the position C(6).




The selective functionalization of uridines is an important synthetic goal because of the biological relevance of many substituted uridines.¹ They are known to display antibiotic, antifungal, anticancer, and antiviral activity. Many antiviral agents are based on modified nucleosides including modifications of both the sugar moiety and the heterocyclic system.² Therefore, the direct lithiation of various uridines has been studied, and the use of dilithiated uridine intermediates has allowed a selective functionalization by tuning the nature of the substituent at the C'(5)-hydroxyl function.^{3a,b,f} Alternatively, the use of halogenated uracils and uridines allows cross-coupling reactions⁴ or the preparation of metalated intermediates via a direct zinc insertion or via a halogen–metal exchange.⁵ A direct Pd-catalyzed C–H arylation of uracils in the presence or absence of CuI allows functionalization of the positions C(5) and C(6).⁶ Although lithium bases⁷ are powerful bases for the direct lithiation of various heterocycles, magnesium or zinc bases are of special interest since they tolerate various functional groups as well as sensitive heterocyclic scaffolds.⁸ Recently, we have reported a selection of mild magnesium and zinc TMP-(2,2,6,6-tetramethylpiperidyl) bases such as $\text{TMPMgCl}\cdot\text{LiCl}$ (**1**)⁹ and $\text{TMP}_2\text{Zn}\cdot 2\text{LiCl}\cdot 2\text{MgCl}_2$ (**2**)¹⁰ which allow a regioselective functionalization of polyfunctionalized aromatics and heterocycles.¹¹ We have demonstrated that a regioselective switch can be achieved by the presence or absence of Lewis acids for a range of metalations.¹² Herein, we report that the bases **1** or **2** allow a highly regioselective metalation at the C(5) or C(6) position of uracils and uridines or at the C(5) position of cytidine. More importantly, we show that these metalated nucleoside derivatives can be quenched with a range of electrophiles.

Preliminary experiments show that $\text{TMPMgCl}\cdot\text{LiCl}$ (**1**, 1.2 equiv, THF, $-40\text{ }^\circ\text{C}$, 4 h) reacts smoothly with *N,N*-dimethyluracil (**3**) to afford the C(5)-magnesiumated uracil (**4**), whereas treatment of **3** with $\text{TMP}_2\text{Zn}\cdot 2\text{LiCl}\cdot 2\text{MgCl}_2$ (**2**, 0.7 equiv, THF, $-30\text{ }^\circ\text{C}$, 48 h) affords the C(6)-zincated uracil (**5**)

with good regioselectivity (C(5)/C(6) = 6:94, Scheme 1). Based on previous studies on the chromone system, we

Scheme 1. MgCl_2 -Triggered Regioselective Magnesiumation and Zincation of Uracil **3** Leading to Products of Type **6** and **7**



^aIsolated yields of regioisomerically pure product. ^bElectrophile used (1.2 equiv). ^cObtained after transmetalation with $\text{CuCN}\cdot 2\text{LiCl}$ (1.2 equiv, $-40\text{ }^\circ\text{C}$, 30 min). ^d2 mol % of $\text{Pd}(\text{dba})_2$, 4 mol % of *t*f_p (25 $^\circ\text{C}$, 2 h). ^eObtained after transmetalation with ZnCl_2 (1.2 equiv, $-40\text{ }^\circ\text{C}$, 30 min), 2 mol % of $\text{Pd}(\text{OAc})_2$, and 4 mol % of XPhos (50 $^\circ\text{C}$, 72 h).


Received: January 20, 2016

Published: February 17, 2016

rationalized the observed regioselectivity by the presence of MgCl_2 (2.0 equiv) in the zinc TMP-base 2.^{12b} This Lewis acid complexes the C(4) carbonyl group and therefore directs the metalation to position C(6) (Scheme 1).¹³ After the resulting metalated nucleosides 4 and 5 were quenched with various electrophiles such as aldehydes, aryl bromides, or iodides (Negishi cross-coupling),¹⁴ allylic halides and acid chlorides (in the presence of $\text{CuCN}\cdot 2\text{LiCl}$),¹⁵ functionalized uracils (6a–c) and (7a–c) were obtained in 69–84% yield.

These reaction conditions were readily applied to protected uridine 8.¹⁶ Its treatment with $\text{TMPMgCl}\cdot\text{LiCl}$ (1, 1.2–1.8 equiv, THF, 40 °C, 24 h) affords the C(5)-magnesiated uridine 9 (C(5):C(6) = 98:2) in >95% yield as determined by ^1H NMR analysis of iodolyzed product 11a (Scheme 2). The

Scheme 2. Reactions and Conditions for C(5) and C(6) Metalation of Uridine 8



presence of MgCl_2 inverses the regioselectivity, and the zincation of 8 with $\text{TMP}_2\text{Zn}\cdot 2\text{LiCl}\cdot 2\text{MgCl}_2$ (2, 1.2 equiv, THF, –30 °C, 72 h) produces the bis-zincated uridine (10) in >95% yield (C(5)/C(6) = 3:97, Scheme 2). With these optimized metalation conditions in hand, a number of C(5)- and C(6)-functionalized uridines were prepared. Reactions of the C(5)-magnesiated uridine 9 with various electrophiles (iodine, alkenyl-, aryl-, and heteroaryl iodides, allylic bromides, acid chlorides, morpholine-4-carbaldehyde, aldehydes, $\text{NC}\cdot\text{CO}_2\text{Et}$, Me_2S_2) produced the expected regioisomerically pure C(5)-substituted uridines (11a–k) in 42–86% yield (entries 1–11, Table 1). Iodolysis of the magnesium reagent 9 provided C(5)-iodinated uridine (11a) in 70% yield (entry 1). Thus, after transmetalation of 9 to zinc, Pd-catalyzed Negishi cross-coupling (8 mol % $\text{Pd}(\text{dba})_2$ ($\text{dba} = \text{trans,trans}$ -dibenzylideneacetone) and 12 mol % of $\text{P}(\text{2-furyl})_3$)¹⁶ with 4-iodoanisole, ethyl 4-iodobenzoate, or 3-iodopyridine provided the products 11b–d (66–81%, entries 2–4). Similarly, copper-mediated allylation with ethyl 2-(bromomethyl)acrylate or bromocyclohexene afforded the C(5)-functionalized uridine derivatives (11e,f) in 73–86% yield (entries 5 and 6). Upon treatment of 9 with ethyl cyanoformate, the functionalized ester (11g) was obtained in 44% yield (entry 7). The ketone (11h) was obtained in 71% yield when 9 was transmetalated to the corresponding copper derivative and acylated with cyclopropanecarbonyl chloride (entry 8). Aldehyde 11i was obtained in 32% yield when 9 was formylated with morpholine-4-carbaldehyde (entry 9). Furthermore, 9 added readily to 4-cyanobenzaldehyde giving the corresponding alcohol 11j (47%,







Table 1. Functionalization of Uridine 8 at C(5) Using $\text{TMP}_2\text{Zn}\cdot\text{LiCl}\cdot 2\text{MgCl}_2$ (2) Leading to Products of Type 11

entry	electrophile/ reaction conditions	product: yield ^a
1	I_2 (1.8 equiv)/ 25 °C; 24 h	 11a: 70%
2	 R = OMe (1.5 equiv)/ 25 °C; 12 h	11b: 81% ^b
3	 R = CO_2Et (1.2 equiv)/ 25 °C; 12 h	11c: 66% ^b
4	 (1.2 equiv)/ 25 °C; 30 min	11d: 73% ^b
5	 (1.2 equiv)/ –40 °C; 10 min and 25 °C; 1 h	11e: 86% ^c
6	 (1.2 equiv)/ –40 °C; 10 min and 25 °C; 1 h	11f: 60% ^c
7	$\text{NC}\cdot\text{CO}_2\text{Et}$ (1.2 equiv)/ –40 to –10 °C; 12 h	11g: 44%
8	 (1.2 equiv)/ –40 to –10 °C; 12 h	11h: 71% ^c
9	 (1.2 equiv)/ 25 °C; 12 h	11i: 32%
10	 (1.2 equiv)/ –40 °C; 10 min and 25 °C; 1 h	11j: 47%
11	MeSSMe (1.2 equiv)/ 25 °C; 1 h	11k: 42%

^aYield of isolated, analytically pure product. ^bObtained after transmetalation with ZnCl_2 (1.2–1.5 equiv, –40 °C, 30 min), 8 mol % of $\text{Pd}(\text{dba})_2$, and 12 mol % of $\text{P}(\text{2-furyl})_3$. ^cObtained after transmetalation with $\text{CuCN}\cdot 2\text{LiCl}$ (1.2 equiv, –40 °C, 30 min).

entry 10). The thioether (**11k**) was obtained in 42% yield when **9** was treated with MeSSMe (entry 11). We also examined the scope of the reaction of C(6) metalated uridine **10** with representative electrophiles (Table 2). Iodolysis of the zinc

Table 2. Functionalization of the Uridine **8 at C(6) Using $\text{TMP}_2\text{Zn}\cdot 2\text{LiCl}\cdot 2\text{MgCl}_2$ (**2**) Leading to Products of Type **12****

entry	electrophile/reaction conditions	product: yield ^a
1	 (2.0 equiv)/25 °C; 30 min	 12a : 95%
2	R = Cl (1.5 equiv)/25 °C; 12 h	 12b : 84% ^b
3	R = CN (1.2 equiv)/25 °C; 12 h	 12c : 69% ^b
4	 (1.2 equiv)/25 °C; 12 h	 12d : 97% ^b
5	 (2.1 equiv)/25 °C; 12 h	 12e : 67% ^c
6	<i>t</i> -BuCOCl (1.2 equiv)/-40 to 0 °C; 12 h	 12f : 97% ^d


^aYield of isolated, analytically pure product. ^bObtained using 8 mol % $\text{Pd}(\text{dba})_2$ and 15 mol % $\text{P}(\text{2-furyl})_3$. ^cObtained using 4 mol % $\text{Pd}(\text{PPh}_3)_4$. ^dObtained after transmetalation with $\text{CuCN}\cdot 2\text{LiCl}$ (1.2 equiv, -40 °C, 30 min).

reagent **10** provided the C(6)-iodinated uridine (**12a**) in 95% yield (entry 1). Pd-catalyzed Negishi cross-coupling (8 mol % of $\text{Pd}(\text{dba})_2$ and 15 mol % of $\text{P}(\text{2-furyl})_3$)¹⁷ with 4-chloriodobenzene, 4-iodobenzonitrile, 2-iodothiophene, or (*E*)-1-iodooctene furnished the expected C(6)-arylated and alkenylated uracils **12b–e** (67–97%, entries 2–5). Similarly, copper-mediated acylation with pivaloyl chloride afforded the C(6) functionalized uridine **12f** (97%, entry 6).

The substitution of the cytidine scaffold is of biological interest, and its lithiation in C(6) is only briefly described in the literature.¹⁸ The bis-Boc-protected cytidine **13**¹⁹ was readily zincated using $\text{TMP}_2\text{Zn}\cdot 2\text{LiCl}\cdot 2\text{MgCl}_2$ (**2**, 1.1–1.2 equiv, THF, -30 °C, 4 h); it gave rise to the C(6)-metalated zinc reagent **14** in 68% yield. This bis-heteroarylzinc was iodolyzed, allylated, acylated, and cross-coupled leading to the expected products **15a–d** (43–61% yield, Scheme 3).²⁰

The selective deprotection of the uridines **11a,h** and **12b,c** could be readily performed using concd HCl to afford the MOM-protected uridines **16a–d** in 72–82%.²⁰ A full


Scheme 3. Reactions and Conditions for the Preparation of C(6)-Substituted Cytidines **14a–d**



^aYield of isolated, analytically pure product. ^b8 mol % $\text{Pd}(\text{dba})_2$, 15 mol % tfp (25 °C, 2 h). ^cObtained after transmetalation with $\text{CuCN}\cdot 2\text{LiCl}$ (1.5 equiv, -40 °C, 30 min).

deprotection of the arylated cytidine **15b** with aqueous $\text{CF}_3\text{CO}_2\text{H}$ resulted in the formation of the cytidine **17** in 85% yield (Scheme 4).

Scheme 4. Deprotection of Substituted Uridines and a Cytidine Leading to the Nucleosides **16a–d and **17****



In summary, we have shown that the presence or absence of MgCl_2 , which is acting as a Lewis acid, allows the efficient and regioselective preparation of metalated uracils, uridines, and cytidine derivatives. The resulting highly functionalized Mg- or Zn-organometallics thereafter react readily with a broad range of electrophiles leading to diversely functionalized uridines at position C(5) or C(6). Applications to the synthesis of biologically active uridines and cytidines are currently underway in our laboratories.

■ ASSOCIATED CONTENT

■ Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.orglett.6b00190.

Full experimental details and NMR data (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: paul.knochel@cup.uni-muenchen.de.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This research has received funding from the Deutsche Forschungsgesellschaft (SFB 749). We also thank BASF AG (Ludwigshafen) and Rockwood Lithium GmbH (Frankfurt) for the generous gift of chemicals.

■ REFERENCES

- (1) (a) von Angerer, S. In *Heteroarenes and Related Ring Systems, Six-Membered Heteroarenes with Two Identical Heteroatoms*. In *Science of Synthesis: Houben-Weyl Methods of Molecular Transformations*; Yamamoto, Y., Ed.; Georg Thieme Verlag: Stuttgart, 2004; Vol. 16, p 379. (b) Rewcastle, G. W. In *Six-membered Rings with Two Heteroatoms, and their Fused Carbocyclic Derivatives*. In *Comprehensive Heterocyclic Chemistry III*; Alan, R. K., Christopher, A. R., Eric, F. V. S., Richard, J. K. T., Eds.; Elsevier: Oxford, 2008; Vol. 8, pp 151–161. (c) Lagoja, I. M. *Chem. Biodiversity* **2005**, 2, 1–50.
- (2) Joule, J. A., Mills, K., Eds. *Heterocyclic Chemistry*, 5th ed.; John Wiley & Sons: West Sussex, 2010; p 661.
- (3) (a) Tanaka, H.; Nasu, I.; Miyasaka, T. *Tetrahedron Lett.* **1979**, 20, 4755–4758. (b) Tanaka, H.; Hayakawa, H.; Miyasaka, T. *Tetrahedron* **1982**, 38, 2635–2642. (c) Hayakawa, H.; Tanaka, H.; Maruyama, Y.; Miyasaka, T. *Chem. Lett.* **1985**, 1401–1404. (d) Tanaka, H.; Hayakawa, H.; Iijima, S.; Haraguchi, K.; Miyasaka, T. *Tetrahedron* **1985**, 41, 861–866. (e) Tanaka, H.; Hayakawa, H.; Obi, K.; Tadashi, M. *Tetrahedron* **1986**, 42, 4187–4195. (f) Hayakawa, H.; Tanaka, H.; Obi, K.; Itoh, M.; Miyasaka, T. *Tetrahedron Lett.* **1987**, 28, 87–90. (g) Shimizu, M.; Tanaka, H.; Hayakawa, H.; Miyasaka, T. *Tetrahedron Lett.* **1990**, 31, 1295–1298. (h) Aso, M.; Ikeno, T.; Norihisa, K.; Tanaka, M.; Koga, N.; Suemune, H. *J. Org. Chem.* **2001**, 66, 3513–3520. (i) Nguyen, N. H.; Len, C.; Castanet, A. S.; Mortier, J. *Beilstein J. Org. Chem.* **2011**, 7, 1228–1233.
- (4) (a) Enderlin, G.; Sartori, G.; Hervé, G.; Len, C. *Tetrahedron Lett.* **2013**, 54, 3374–3377. (b) Yamamoto, Y.; Seko, T.; Nemoto, H. *J. Org. Chem.* **1989**, 54, 4734–4736. (c) Macíčková-Cahová, H.; Pohl, R.; Horáková, P.; Havran, L.; Špaček, J.; Fojta, M.; Hocek, M. *Chem. - Eur. J.* **2011**, 17, 5833–5841.
- (5) (a) Stevenson, T. M.; Prasad, B. A. S.; Citineni, J. R.; Knochel, P. *Tetrahedron Lett.* **1996**, 37, 8375–8378. (b) Bhanu Prasad, A. S.; Stevenson, T. M.; Citineni, J. R.; Nyzam, V.; Knochel, P. *Tetrahedron* **1997**, 53, 7237–7254. (c) Bhanu Prasad, A. S.; Knochel, P. *Tetrahedron* **1997**, 53, 16711–16720. (d) Ulbricht, T. L. V. *Tetrahedron* **1959**, 6, 225–231. (e) Boudet, N.; Knochel, P. *Org. Lett.* **2006**, 8, 3737–3740. (f) Kopp, F.; Knochel, P. *Org. Lett.* **2007**, 9, 1639–1641.
- (6) Čerňová, M.; Čerňa, I.; Pohl, R.; Hocek, M. *J. Org. Chem.* **2011**, 76, 5309–5319.
- (7) (a) Clayden, J. *Organolithiums: Selectivity for Synthesis*; Baldwin, J. E., Williams, R. M., Eds.; Elsevier: Oxford, 2002. (b) *The Chemistry of Organolithium Compounds*; Rappoport, Z., Marek, I., Eds.; John Wiley and Sons: Chichester, 2004. (c) Beak, P.; Snieckus, V. *Acc. Chem. Res.* **1982**, 15, 306–312. (d) Snieckus, V. *Chem. Rev.* **1990**, 90, 879–933. (e) Whisler, M. C.; MacNeil, S.; Snieckus, V.; Beak, P. *Angew. Chem.* **2004**, 116, 2256–2276; *Angew. Chem., Int. Ed.* **2004**, 43, 2206–2225. (f) L'Helgoual, J. M.; Seggio, A.; Chevallier, F.; Yonehara, M.; Jeanneau, E.; Uchiyama, M.; Mongin, F. *J. Org. Chem.* **2008**, 73, 177–183. (g) Mulvey, R. E.; Robertson, S. D. *Angew. Chem.* **2013**, 125, 11682–11700; *Angew. Chem., Int. Ed.* **2013**, 52, 11470–11487.
- (8) (a) Wunderlich, S.; Knochel, P. *Chem. Commun.* **2008**, 6387–6389. (b) Mosrin, M.; Petrera, M.; Knochel, P. *Synthesis* **2008**, 2008, 3697–3702. (c) Mosrin, M.; Bresser, T.; Knochel, P. *Org. Lett.* **2009**, 11, 3406–3409. (d) Mosrin, M.; Knochel, P. *Chem. - Eur. J.* **2009**, 15, 1468–1477. (e) Zimdars, S.; Mollat du Jourdin, X.; Crestey, F.; Carell, T.; Knochel, P. *Org. Lett.* **2011**, 13, 792–795. (f) Sämman, C.; Coysa, E.; Knochel, P. *Angew. Chem.* **2014**, 126, 1454–1458; *Angew. Chem., Int. Ed.* **2014**, 53, 1430–1434. (g) Nafe, J.; Knochel, P. *Synthesis* **2015**, 48, 103–114.
- (9) Krasovskiy, A.; Krasovskaya, V.; Knochel, P. *Angew. Chem.* **2006**, 118, 3024–3027; *Angew. Chem., Int. Ed.* **2006**, 45, 2958–2961.
- (10) Wunderlich, S.; Knochel, P. *Angew. Chem.* **2007**, 119, 7829–7832; *Angew. Chem., Int. Ed.* **2007**, 46, 7685–7688.
- (11) For recent reviews, see: (a) Haag, B.; Mosrin, M.; Ila, H.; Malakhov, V.; Knochel, P. *Angew. Chem.* **2011**, 123, 9968–9999; *Angew. Chem., Int. Ed.* **2011**, 50, 9794–9824. (b) Klatt, T.; Markiewicz, J. T.; Sämman, C.; Knochel, P. *J. Org. Chem.* **2014**, 79, 4253–4269.
- (12) (a) Jaric, M.; Haag, B. A.; Manolikakes, S.; Knochel, P. *Org. Lett.* **2011**, 13, 2306–2309. (b) Klier, L.; Bresser, T.; Nigst, T. A.; Karaghiosoff, K.; Knochel, P. *J. Am. Chem. Soc.* **2012**, 134, 13584–13587. (c) Groll, K.; Manolikakes, S. M.; Mollat du Jourdin, X.; Jaric, M.; Bredihhin, A.; Karaghiosoff, K.; Carell, T.; Knochel, P. *Angew. Chem., Int. Ed.* **2013**, 52, 6776–6780. (d) Klatt, T.; Roman, D. S.; Leon, T.; Knochel, P. *Org. Lett.* **2014**, 16, 1232–1235. (e) Frischmuth, A.; Fernández, M.; Barl, N. M.; Achraimer, F.; Zipse, H.; Berionni, G.; Mayr, H.; Karaghiosoff, K.; Knochel, P. *Angew. Chem.* **2014**, 126, 8062–8066; *Angew. Chem., Int. Ed.* **2014**, 53, 7928–7932.
- (13) Only a moderate regioselectivity is obtained in the absence of the Lewis acid (MgCl₂); see also ref 12b.
- (14) (a) Negishi, E.; Valente, L. F.; Kobayashi, M. *J. Am. Chem. Soc.* **1980**, 102, 3298–3299. (b) Kobayashi, M.; Negishi, E. *J. Org. Chem.* **1980**, 45, 5223–5225. (c) Negishi, E. *Acc. Chem. Res.* **1982**, 15, 340–348.
- (15) Knochel, P.; Yeh, M. C. P.; Berk, S. C.; Talbert, J. *J. Org. Chem.* **1988**, 53, 2390–2392.
- (16) Nguyen, N. H.; Len, C.; Castanet, A. S.; Mortier, J. *Beilstein J. Org. Chem.* **2011**, 7, 1228–1233.
- (17) (a) Farina, V.; Krishnan, B. *J. Am. Chem. Soc.* **1991**, 113, 9585–9595. (b) Farina, V.; Kapadia, S.; Krishnan, B.; Wang, C.; Liebeskind, L. *J. Org. Chem.* **1994**, 59, 5905–5911.
- (18) (a) Aso, M.; Ikeno, T.; Norihisa, K.; Tanaka, M.; Koga, N.; Suemune, H. *J. Org. Chem.* **2001**, 66, 3513–3520. (b) Aso, M.; Kaneko, T.; Nakamura, M.; Matsui, Y.; Koga, N.; Suemune, H. *Nucleic Acids Symp. Ser.* **2003**, 3, 9–10.
- (19) Bazzanini, R.; Gouy, M. H.; Peyrottes, S.; Gosselin, G.; Périgaud, C.; Manfredini, S. *Nucleosides, Nucleotides Nucleic Acids* **2005**, 24, 1635–1649.
- (20) (a) Dai, Q.; Piccirilli, J. A. *Org. Lett.* **2003**, 5, 807–810. (b) Kurosu, M.; Biswas, K.; Crick, D. C. *Org. Lett.* **2007**, 9, 1141–1144. (c) Bello, A. M.; Poduch, E.; Fujihashi, M.; Amani, M.; Li, Y.; Crandall, I.; Hui, R.; Lee, P. I.; Kain, K. C.; Pai, E. F.; Kotra, L. P. *J. Med. Chem.* **2007**, 50, 915–921. (d) Hospital, A.; Périgaud, C. *Org. Lett.* **2013**, 15, 4778–4781. (e) Shih, Y.-C.; Chien, T.-C. *Tetrahedron* **2011**, 67, 3915–3923.